Last mentioned: Mar 4, 2026
FY 2025 Earnings
Released full-year financial results and updated 2026 clinical guidance.
FY 2025 Earnings
Official reporting of full-year financial results and 2026 clinical guidance.
FY2025 Earnings
Released full-year results highlighting commercial scaling and Colorado facility progress.
Anticipated Data
Expected top-line data readouts for multiple Phase 2 programs.
Cibotercept Data
Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
Brighton Fab Launch
Expected commencement of high-volume manufacturing in Colorado.
Cibotercept Progress
Initiated additional cohorts in PAH studies to evaluate dose-response.
KER-050 Expansion
Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
500 Wh/kg Milestone
Verified performance of 500 Wh/kg cells with key aerospace partners.
Trial Expansion
Keros expanded the TROPOS trial to include broader MDS patient populations.
Capital Infusion
Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
Capacity Expansion
Amprius increased production capacity at its Fremont pilot line to meet initial eVTOL demand.
Amprius Technologies reported its full-year 2025 financial results, highlighting a critical transition from pilot-scale production to industrial commercialization of its high-energy silicon anode batteries. The company is positioning its ultra-high-density storage solutions as the primary enabler for the burgeoning eVTOL and defense aviation sectors.
Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.